CareConnect Personalized Support | Cerezyme®

Connected care personalized to your patients

Connected Education:

Comprehensive disease education from diagnosis and beyond for individuals, families, and communities.

Connected Team:

Experts who connect the dots between specialists, insurance, and appointments for a less fragmented care experience.

Connected Experience:

Programs designed to support patients by connecting them with experts and the community to navigate life transitions and manage treatment.

If affording treatment is an issue, CareConnect may be able to help eligible patients access financial assistance.

Connect with us

Enroll at www.careconnectpss.com.
Call 1-800-745-4447, option 3, or email info@CareConnectPSS.com.

Have questions about Cerezyme^® (imiglucerase)?

Your local representative can help provide answers

Request a rep →

Looking for more treatment information?

Access downloadable resources

Visit downloadable resources →

Indication

Indication and Usage:

Cerezyme^® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:

anemia
thrombocytopenia
bone disease
hepatomegaly or splenomegaly

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur.

Warnings and Precautions:

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.
Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Consider periodic monitoring during the first year of treatment for lgG antibody formation.

Consider risks and benefits of readministering Cerezyme to individual patients following a severe reaction. Consider reducing the rate of infusion, pretreat with antihistamines and/or corticosteroids, and monitor patients for new signs and symptoms of a severe hypersensitivity reaction.

Infusion-Associated Reactions:
Infusion associated reactions (IARs) have been observed in patients treated with Cerezyme. If an IAR occurs, decreasing the infusion rate, temporarily stopping the infusion and/or administering antihistamines and/or antipyretics may ameliorate the symptoms. Closely monitor patients who have experienced IARs when re-administering Cerezyme.

Adverse Reactions:
Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting.

Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults.

Please see full Prescribing Information, including Boxed WARNING.

CareConnect™ Personalized Support Services

Connected care personalized to your patients

Connected Education:

Connected Team:

Connected Experience:

If affording treatment is an issue, CareConnect may be able to help eligible patients access financial assistance.

Connect with us

Have questions about Cerezyme® (imiglucerase)?

Looking for more treatment information?

Indication

Indication and Usage:

Important Safety Information

Warnings and Precautions:

Indication

Important Safety Information

Have questions about Cerezyme^® (imiglucerase)?